NTRK1 Antibody

What is NTRK1 and why is it significant in research?

NTRK1 (neurotrophic receptor tyrosine kinase 1) is a high-affinity receptor for nerve growth factor (NGF) with essential roles in the development and maturation of the central and peripheral nervous systems. It functions by regulating the proliferation, differentiation, and survival of sympathetic and nervous neurons . The protein is approximately 87.5 kilodaltons in mass and is also known by several alternative names including TrkA, MTC, TRK1, high affinity nerve growth factor receptor, and Oncogene TRK .

NTRK1 is significant in research for several reasons:

• It serves as a critical regulator of neuronal development and survival

• It functions in signaling pathways relevant to cancer and other diseases

• Recent evidence indicates its role in immune regulation, particularly in the context of cancer immunotherapy

• It serves as a molecular marker for specific brain regions, such as the paraventricular thalamic nucleus (PVT)

To study NTRK1 effectively, researchers must carefully select validated antibodies that recognize the target with high specificity across different experimental applications.

How should researchers select an appropriate NTRK1 antibody for their studies?

When selecting an NTRK1 antibody, researchers should consider multiple factors to ensure experimental success:

• Experimental application compatibility: Verify that the antibody has been validated for your specific application (WB, ELISA, IHC, IF, etc.). For instance, search results show that NTRK1 antibodies are available for various applications including Western Blot, ELISA, immunohistochemistry, and flow cytometry .

• Species reactivity: Confirm the antibody recognizes NTRK1 in your model organism. Commercial antibodies show varying patterns of reactivity - some recognize human NTRK1 exclusively, while others cross-react with mouse, rat, or other species .

• Antibody validation: Look for antibodies validated using knockout controls. Recent research demonstrated that only one of seven commercial antibodies exhibited true specificity when tested against brain lysates from Ntrk1 knockout mice .

• Clonality and host species: Determine whether a monoclonal or polyclonal antibody is more suitable for your research question, and consider how the host species might affect your experimental design, particularly for multiple labeling studies.

• Immunogen information: Review the specific peptide or protein region used to generate the antibody, as this affects the epitope recognized. For example, one commercial antibody uses a KLH-conjugated synthetic peptide derived from human NTRK1 in the range of amino acids 725-796 .

Always request validation data from manufacturers and consider performing your own validation using positive and negative controls relevant to your experimental system.

What are the critical quality control measures for validating NTRK1 antibodies?

Proper validation of NTRK1 antibodies is essential for generating reliable research data. Implement these critical quality control measures:

• Genetic knockout controls: The gold standard for antibody validation involves testing in tissues or cells lacking the target protein. Research shows that using Ntrk1 knockout mice brain lysates effectively identified one specific antibody among seven commercial options tested .

• Expression pattern confirmation: Verify that the antibody detects NTRK1 in tissues known to express the protein. For NTRK1, this includes specific brain regions such as the striatum, basal forebrain, and the paraventricular thalamic nucleus with its characteristic anterior-posterior expression gradient .

• Band size verification: For Western blot applications, confirm that the detected protein corresponds to the expected molecular weight of approximately 87.5 kDa for NTRK1 .

• Correlation with mRNA expression: Compare antibody staining patterns with known mRNA expression data from techniques like in situ hybridization or RNA sequencing.

• Multiple antibody concordance: Use multiple antibodies targeting different epitopes of NTRK1 and compare results for consistency.

• Specificity controls: Include appropriate blocking peptides, pre-adsorption controls, or isotype controls to ensure signal specificity.

Researchers should document these validation steps thoroughly and include them in publications to enhance reproducibility in the field.

How does NTRK1 signaling affect immune checkpoint inhibitor efficacy in cancer?

NTRK1 signaling has emerged as an important modulator of immune checkpoint inhibitor (ICI) efficacy, particularly in non-small cell lung cancer (NSCLC). Recent research reveals several key mechanisms:

These findings suggest that NTRK1 inhibition represents a potential therapeutic strategy to overcome immunotherapy resistance in NSCLC patients with wild-type NTRK1. Researchers investigating cancer immunotherapy should consider NTRK1 status when designing studies and analyzing treatment responses.

What are the challenges in detecting NTRK1 in neurological tissue samples and how can they be overcome?

Detecting NTRK1 in neurological tissues presents several unique challenges that require careful methodological consideration:

• Antibody specificity issues: Recent research demonstrated that only one out of seven commercially available antibodies showed true specificity when tested against brain lysates from Ntrk1 knockout mice . This highlights the critical importance of antibody validation before conducting neurological tissue studies.

• Region-specific expression patterns: NTRK1 expression in the brain is highly localized to specific regions such as the striatum, basal forebrain, and paraventricular thalamic nucleus (PVT) . This restricted expression pattern can lead to false negatives if sampling is not precise.

• Anterior-posterior expression gradients: The PVT exhibits differential NTRK1 expression, with higher levels in the anterior portion and lower levels in the posterior portion . This gradient requires careful sectioning and anatomical positioning during analysis.

To overcome these challenges:

• Use knockout-validated antibodies: Select antibodies that have been specifically validated using Ntrk1 knockout tissue controls .

• Implement complementary detection methods: Combine immunohistochemistry with in situ hybridization or RNAscope to confirm protein localization patterns.

• Employ stereotaxic coordinates: Use precise stereotaxic mapping when analyzing brain regions to account for anterior-posterior expression gradients.

• Include positive control regions: Always include known NTRK1-expressing regions (e.g., striatum) as positive controls in your experimental design.

• Optimize fixation protocols: Test multiple fixation methods to determine optimal conditions for NTRK1 epitope preservation in neural tissues.

Careful attention to these methodological details will enhance the reliability and reproducibility of NTRK1 detection in neurological tissue samples.

How can researchers distinguish between NTRK1 and related family members (NTRK2/NTRK3) in experimental systems?

Distinguishing between NTRK family members (NTRK1/TrkA, NTRK2/TrkB, and NTRK3/TrkC) is crucial for accurate research outcomes due to their structural similarities but distinct functional roles. Consider these methodological approaches:

• Antibody epitope selection: Choose antibodies targeting less conserved regions of NTRK1. The extracellular domain and the C-terminal tail exhibit greater sequence divergence than the highly conserved kinase domain. Some commercial antibodies target the C-terminal region (e.g., amino acids 725-796/796) , which may provide better specificity.

• Isoform-specific primers: For mRNA detection, design PCR primers spanning unique exon junctions or targeting isoform-specific sequences. Validate primers using positive controls expressing individual NTRK family members.

• Knockout validation: Test antibody cross-reactivity using samples from NTRK1, NTRK2, and NTRK3 knockout models. Recent research validated one specific NTRK1 antibody using Ntrk1 knockout mice .

• Ligand-based functional assays: Exploit the differential binding preferences of neurotrophins to distinguish between NTRK family members:

  • NGF binds preferentially to NTRK1

  • BDNF and NT-4/5 bind preferentially to NTRK2

  • NT-3 primarily binds NTRK3 but can also activate NTRK1 and NTRK2

• Expression pattern analysis: Utilize the distinct expression patterns of NTRK family members in different tissues as an additional validation approach. NTRK1 shows characteristic expression in specific brain regions such as the striatum, basal forebrain, and paraventricular thalamic nucleus .

By combining these approaches, researchers can confidently distinguish between NTRK family members in their experimental systems.

What are the optimal protocols for using NTRK1 antibodies in Western blotting?

Optimizing Western blot protocols for NTRK1 detection requires attention to several key factors:

• Sample preparation:

  • For neurological tissue: Rapid extraction and processing are essential. Homogenize brain tissues in RIPA buffer containing both protease and phosphatase inhibitors.

  • For cell lines: Lyse cells directly in laemmli buffer for increased protein recovery.

• Protein loading and transfer:

  • Load adequate protein (30-50 μg for tissue lysates, 15-30 μg for cell lysates)

  • Use a lower percentage gel (7-8%) to better resolve the 87.5 kDa NTRK1 protein

  • Transfer to PVDF membranes at lower voltage for longer time to ensure complete transfer of larger proteins

• Antibody selection and dilution:

  • Choose an antibody validated specifically for Western blotting applications

  • Typical working dilutions range from 1:500 to 1:2000, but optimize based on the specific antibody

  • A validated commercial NTRK1 antibody concentration is reported as 1μg/μl

• Controls and validation:

  • Include positive controls from tissues known to express NTRK1 (e.g., striatum or basal forebrain)

  • Where possible, include negative controls from Ntrk1 knockout samples

  • Verify signal specificity by checking for the expected 87.5 kDa band

• Troubleshooting common issues:

  • Multiple bands: May indicate isoforms, proteolytic fragments, or non-specific binding

  • No signal: Check protein loading, transfer efficiency, and antibody dilution

  • High background: Optimize blocking conditions and increase washing steps

By following these guidelines, researchers can achieve specific and reproducible detection of NTRK1 in Western blotting applications.

How should researchers optimize immunohistochemistry protocols for NTRK1 detection in different tissue types?

Optimizing immunohistochemistry (IHC) protocols for NTRK1 detection requires tailored approaches for different tissue types:

• Brain tissue-specific considerations:

  • Perfusion fixation with 4% paraformaldehyde is recommended for optimal morphology

  • Carefully map brain regions as NTRK1 shows highly specific expression patterns in areas such as the striatum, basal forebrain, and paraventricular thalamic nucleus

  • For the paraventricular thalamic nucleus, note the anterior-posterior gradient of NTRK1 expression

  • Antigen retrieval is critical: test both heat-mediated (citrate buffer, pH 6.0) and enzymatic methods

• Tumor tissue considerations:

  • For formalin-fixed, paraffin-embedded (FFPE) samples, extend antigen retrieval time

  • Consider dual staining with immune cell markers when studying NTRK1's role in tumor-immune interactions

  • Use serial sections to correlate NTRK1 expression with immune cell infiltration

• Antibody selection and validation:

  • Choose antibodies specifically validated for IHC applications

  • Verify specificity using tissues from Ntrk1 knockout animals as negative controls

  • Optimize antibody concentration through titration experiments

• Signal detection and amplification:

  • For low-expression samples, consider tyramide signal amplification

  • For co-localization studies, use fluorescent secondary antibodies

  • For chromogenic detection, DAB works well but adjust development time carefully

• Protocol optimization table:

Following these tissue-specific optimizations will enhance the specificity and sensitivity of NTRK1 detection in immunohistochemistry applications.

What strategies can improve the detection of low-abundance NTRK1 in experimental samples?

Detecting low-abundance NTRK1 presents challenges that require specialized approaches:

• Sample enrichment techniques:

  • For tissue samples: Use laser capture microdissection to isolate specific NTRK1-expressing regions such as the striatum or basal forebrain

  • For cells: Consider immunoprecipitation of NTRK1 before Western blotting to concentrate the protein

  • For membrane proteins: Use membrane fractionation to reduce background from cytosolic proteins

• Signal amplification methods:

  • For Western blotting: Implement enhanced chemiluminescence (ECL) plus or femto-sensitivity detection systems

  • For immunohistochemistry: Use tyramide signal amplification (TSA) or polymer-based detection systems

  • For immunofluorescence: Consider quantum dots or fluorescent-labeled tyramide amplification

• Optimized antibody strategies:

  • Use antibodies with validated high affinity and specificity for NTRK1

  • Consider a sandwich approach using two antibodies recognizing different NTRK1 epitopes

  • Employ longer primary antibody incubation times (overnight at 4°C) to improve signal

• Reduction of background and non-specific signals:

  • Implement stringent blocking with 5% BSA or 5% milk with 0.1-0.3% Triton X-100

  • Include multiple wash steps using buffers with increased salt concentration

  • Use knockout or knockdown controls to distinguish specific from non-specific signals

• Alternative detection methods:

  • Consider RNAscope or BaseScope for sensitive detection of NTRK1 mRNA

  • Use proximity ligation assay (PLA) to detect protein-protein interactions involving NTRK1

  • Implement more sensitive mass spectrometry-based approaches for protein identification

By combining these strategies, researchers can significantly improve the detection of low-abundance NTRK1 in experimental samples, enabling more accurate characterization of its expression patterns and functions.

How does NTRK1 expression and signaling vary across different brain regions and what are the functional implications?

NTRK1 exhibits highly specific expression patterns across brain regions, with significant functional implications:

• Region-specific expression patterns:

  • Basal forebrain and striatum: NTRK1 is prominently expressed in cholinergic neurons in these regions, supporting their development and maintenance

  • Paraventricular thalamic nucleus (PVT): Recent research confirmed differential NTRK1 expression with high levels in the anterior PVT and lower levels in the posterior PVT

  • Non-basal forebrain cholinergic cells: A more widespread distribution of NTRK1 has been reported in these neurons, suggesting broader functions beyond cholinergic signaling

• Developmental regulation:

  • NTRK1 expression is dynamically regulated during neurodevelopment, with critical roles in neuronal survival, axon extension, and synaptic plasticity

  • Temporal expression patterns correlate with critical periods of nervous system development

• Signaling mechanisms:

  • Upon binding its primary ligand NGF, NTRK1 undergoes homodimerization, autophosphorylation, and activation

  • This activation recruits and phosphorylates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2, and PLCG1

  • These effectors regulate distinct overlapping signaling cascades that drive cell survival and differentiation

  • Through SHC1 and FRS2, NTRK1 activates a GRB2-Ras-MAPK cascade regulating cell differentiation and survival

  • Through PLCG1, NTRK1 controls NF-Kappa-B activation

• Functional implications:

  • In the basal forebrain and striatum, NTRK1 signaling is essential for cholinergic neuron maintenance, with implications for cognitive function

  • In the PVT, the anterior-posterior gradient of NTRK1 expression suggests differential roles in emotion processing and stress responses

  • The broader distribution in non-cholinergic neurons indicates potential roles in other neuronal populations

Understanding these region-specific expression patterns and signaling mechanisms is crucial for interpreting experimental results and developing targeted therapeutic approaches for neurological disorders.

What are the emerging roles of NTRK1 in the tumor microenvironment and cancer immunotherapy?

Recent research has uncovered critical roles for NTRK1 in modulating the tumor microenvironment and influencing immunotherapy responses:

These findings highlight the importance of NTRK1 in regulating cross-talk between tumor cells and immune cells within the tumor microenvironment and suggest new therapeutic strategies for overcoming immunotherapy resistance in cancer patients.

What methodological approaches can help resolve contradictory findings in NTRK1 research literature?

The research literature on NTRK1 contains several apparent contradictions that can be resolved through careful methodological approaches:

• Antibody validation discrepancies:

  • Problem: Different studies report conflicting NTRK1 expression patterns due to antibody specificity issues

  • Solution: Recent research demonstrated that only one of seven tested commercial antibodies showed true specificity against NTRK1 knockout controls

  • Methodological approach: Always validate antibodies using genetic knockout models and report detailed validation methods in publications

• Species-specific differences:

  • Problem: NTRK1 function and expression patterns may vary between species, leading to contradictory findings

  • Solution: Clearly distinguish between species when reporting results and avoid direct cross-species comparisons without validation

  • Methodological approach: Use species-specific antibodies with verified reactivity and conduct parallel experiments in multiple species when making comparative claims

• Regional expression heterogeneity:

  • Problem: Reports of NTRK1 expression in the brain vary based on the precise regions examined

  • Solution: The paraventricular thalamic nucleus (PVT) exhibits an anterior-posterior gradient of NTRK1 expression that might explain seemingly contradictory results

  • Methodological approach: Use precise stereotaxic coordinates and systematic sampling across brain regions to account for expression gradients

• Experimental protocol standardization:

  • Problem: Variations in sample preparation, fixation methods, and detection protocols contribute to contradictory findings

  • Solution: Implement standardized protocols for tissue processing and antibody application

  • Methodological approach: Document all experimental conditions comprehensively, including:

    • Fixation method and duration

    • Antigen retrieval protocol

    • Blocking solution composition

    • Antibody dilution and incubation conditions

    • Detection system specifications

• Data reconciliation framework:

By implementing these methodological approaches, researchers can help resolve contradictions in the NTRK1 literature and advance understanding of this important signaling molecule.

What emerging technologies might enhance NTRK1 research in neurological and cancer studies?

Several emerging technologies show promise for advancing NTRK1 research across neurological and cancer studies:

• Single-cell technologies:

  • Single-cell RNA sequencing can reveal cell-type-specific NTRK1 expression patterns in heterogeneous tissues

  • Single-cell proteomics may enable detection of NTRK1 protein levels and phosphorylation states at the individual cell level

  • Spatial transcriptomics can map NTRK1 expression within complex tissue architectures while preserving spatial context

• Advanced imaging approaches:

  • Super-resolution microscopy (STORM, PALM) can visualize NTRK1 distribution at nanoscale resolution

  • Expansion microscopy combined with cleared tissue techniques may enhance detection of NTRK1 in intact brain regions

  • Multiplexed ion beam imaging (MIBI) or co-detection by indexing (CODEX) can simultaneously visualize NTRK1 alongside dozens of other proteins

• Functional genomics tools:

  • CRISPR-Cas9 screening approaches can systematically identify genes that modulate NTRK1 signaling in neuronal or cancer contexts

  • CRISPR activation/interference systems allow temporal control of NTRK1 expression

  • Base editing or prime editing technologies enable precise introduction of NTRK1 mutations found in patient samples

• Organoid and 3D culture systems:

  • Brain organoids can model NTRK1 function in developing neural systems

  • Tumor organoids with intact immune components can investigate NTRK1's role in tumor-immune interactions

  • Microfluidic organ-on-chip platforms may reveal NTRK1's role in cell migration and neurite outgrowth

• In vivo tools:

  • Genetically encoded biosensors for NTRK1 activity

  • Transparent tissue clearing methods combined with light-sheet microscopy for whole-brain NTRK1 mapping

  • Chemogenetic or optogenetic modulation of NTRK1-expressing neurons to assess functional consequences

These emerging technologies will likely transform our understanding of NTRK1 biology by providing unprecedented resolution, throughput, and functional insights across neurological and cancer research domains.

How can researchers design experiments to better understand the differential effects of NTRK1 signaling in normal versus disease states?

Designing experiments to distinguish NTRK1 functions between normal and disease states requires sophisticated approaches:

• Cell-type specific manipulation strategies:

  • Use Cre-loxP systems with cell-type-specific promoters to conditionally delete or express NTRK1

  • Implement inducible systems (e.g., tetracycline-controlled) to modulate NTRK1 expression at defined disease stages

  • Apply viral vectors with cell-type-specific promoters for targeted NTRK1 modulation in adult tissues

• Temporal control of NTRK1 signaling:

  • Design experiments using rapid chemical-genetic approaches like "bump-and-hole" kinase inhibitors for NTRK1

  • Implement optogenetic control of NTRK1 signaling components for precise temporal manipulation

  • Use degrader technologies (PROTACs) for rapid and reversible NTRK1 protein depletion

• Comprehensive signaling analysis:

  • Compare phosphoproteomic profiles downstream of NTRK1 between normal and disease states

  • Implement proximity labeling approaches (BioID, APEX) to identify context-specific NTRK1 interaction partners

  • Use FRET-based biosensors to monitor NTRK1 activation dynamics in living cells

• Integrative experimental design framework:

• Disease-specific considerations:

  • For cancer studies: Compare NTRK1 signaling in matched tumor and adjacent normal tissues; design experiments to dissect NTRK1's role in tumor-immune interactions as revealed in recent immune checkpoint inhibitor studies

  • For neurological studies: Leverage the specific expression patterns of NTRK1 in regions like the paraventricular thalamic nucleus to understand region-specific pathology

By implementing these experimental design strategies, researchers can more effectively differentiate the context-dependent roles of NTRK1 signaling between normal physiological function and disease pathogenesis.

What are the key methodological considerations for translating NTRK1 research findings into clinical applications?

Translating NTRK1 research findings into clinical applications requires careful attention to several methodological considerations:

• Antibody validation for diagnostic applications:

  • Implement rigorous validation using multiple methodologies (Western blot, IHC, flow cytometry)

  • Verify antibody specificity using knockout controls as demonstrated in recent research

  • Establish standardized scoring systems for NTRK1 expression in clinical samples

  • Develop companion diagnostic assays with carefully validated antibodies

• Patient stratification approaches:

  • Design trials that stratify patients based on NTRK1 mutation or expression status

  • Recent findings suggest that NSCLC patients with NTRK1 loss-of-function mutations may respond better to immune checkpoint inhibitors

  • Develop multi-parameter stratification approaches that combine NTRK1 status with other biomarkers

• Combination therapy design:

  • Create rational combinations based on mechanistic understanding of NTRK1 signaling

  • Research suggests combining NTRK1 inhibitors with immune checkpoint inhibitors may enhance efficacy in NSCLC

  • Test drug sequences and schedules to optimize therapeutic window and minimize toxicity

• Translational pipeline considerations:

• Target engagement and resistance monitoring:

  • Develop methods to confirm NTRK1 inhibition in patient samples

  • Implement serial biopsies or liquid biopsy approaches to monitor for resistance

  • Design adaptive trials that modify treatment based on changes in NTRK1 signaling

• Ethical and regulatory considerations:

  • Address off-target effects of NTRK1-targeted therapies on neurological function

  • Establish risk-benefit profiles based on patient-specific NTRK1 expression patterns

  • Develop specific regulatory guidance for NTRK1-targeted therapeutics and diagnostics